We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

90 hedge funds and large institutions have $343M invested in CytomX Therapeutics in 2017 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 42 increasing their positions, 14 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 14

27% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 15

7.76% more ownership

Funds ownership: 52.39% → 60.15% (+7.8%)

5% more funds holding

Funds holding: 86 → 90 (+4)

3% more capital invested

Capital invested by funds: $332M → $343M (+$11.1M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
90
Holders Change
+4
Holders Change %
+4.65%
% of All Funds
2.24%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
19
Increased
42
Reduced
14
Closed
15
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$12.1M
2
NI
Numeric Investors
Massachusetts
+$9.46M
3
BI
BVF Inc
California
+$3.35M
4
Renaissance Technologies
Renaissance Technologies
New York
+$2.65M
5
State Street
State Street
Massachusetts
+$2.49M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$2.81M
2
PA
Perceptive Advisors
New York
-$2.11M
3
MBT
Montecito Bank & Trust
California
-$1.78M
4
PAG
Private Advisor Group
New Jersey
-$1.46M
5
PI
Putnam Investments
Massachusetts
-$1.29M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$85.4M +$524K +34,732 +0.6%
BI
2
BVF Inc
California
$31.4M +$3.35M +222,323 +12%
BlackRock
3
BlackRock
New York
$28.1M +$12.1M +800,528 +79%
PA
4
Perceptive Advisors
New York
$21.6M -$2.11M -140,278 -9%
Vanguard Group
5
Vanguard Group
Pennsylvania
$14.3M +$1.52M +100,607 +12%
EC
6
EcoR1 Capital
California
$12.3M – – –
DM
7
Deerfield Management
New York
$11.7M -$2.81M -186,611 -20%
RG
8
Redmile Group
California
$10.8M +$249K +16,500 +2%
NI
9
Numeric Investors
Massachusetts
$9.73M +$9.46M +627,770 New
TCM
10
Tekla Capital Management
Massachusetts
$8.22M – – –
OM
11
Opaleye Management
Massachusetts
$7.13M +$1.81M +120,000 +35%
State Street
12
State Street
Massachusetts
$6.91M +$2.49M +165,342 +59%
Renaissance Technologies
13
Renaissance Technologies
New York
$6.37M +$2.65M +176,100 +75%
Franklin Resources
14
Franklin Resources
California
$5.17M – – –
Northern Trust
15
Northern Trust
Illinois
$4.91M +$1.28M +84,602 +36%
DCM
16
Driehaus Capital Management
Illinois
$4.5M -$64.5K -4,279 -1%
VMI
17
VHCP Management II
New York
$4.48M – – –
JP Morgan Chase
18
JP Morgan Chase
New York
$3.76M +$859K +56,972 +31%
T. Rowe Price Associates
19
T. Rowe Price Associates
Maryland
$3.76M +$1.42M +94,385 +64%
SIM
20
Spark Investment Management
New York
$3.67M +$2.04M +135,200 +133%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$3.64M +$393K +26,053 +12%
CAM
22
Cormorant Asset Management
Massachusetts
$3.56M – – –
SFM
23
Sphera Funds Management
Israel
$3.1M +$754K +50,000 +33%
CS
24
Candriam SCA
Luxembourg
$3.02M – – –
CC
25
Casdin Capital
New York
$2.75M – – –
1
2 3 4 5

CTMX Hedge Fund Activity: Q2 2017 in Review

90 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2017, worth a combined $343M — up 3.4% from $332M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new CTMX positions and 15 closed out — a net gain of 4 holders — while 42 added to existing stakes and 14 trimmed.

The largest buyer was BlackRock, adding an estimated $12.1M. The largest seller was Deerfield Management, cutting an estimated $2.81M.

  • 90 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2017, up from 86 in Q1 2017.
  • Funds reported $343M of CytomX Therapeutics stock for Q2 2017, up 3.4% quarter-over-quarter.
  • 19 funds opened new CytomX Therapeutics positions in Q2 2017 and 15 closed out, a net change of +4 holders.
  • The largest CytomX Therapeutics buyer in Q2 2017 was BlackRock, an estimated $12.1M added.
  • The largest CytomX Therapeutics seller in Q2 2017 was Deerfield Management, an estimated $2.81M sold.

Based on aggregated 13F filings for Q2 2017.